It is a heterogeneous group of pathologic entities, and three subtypes of breast tumors that differ in biologic behavior were identified through immunohistochemistry techniques: hormone receptor-positive, human epidermal receptor (HER2/neu) positive, and triple negative breast cancers (TNBCs), and each of these requires a specific management approach (Bianchini et al., 2016). Here, ERBB2 is linked to triple-negative breast carcinoma.